Eye/Orbit

For questions about these or other cancer clinical trials, please contact our Cancer Research Navigator at 949-764-2704 or lauren.wagner@hoag.org.

(146-22) LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor

(148-24) A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Subjects with Carcinoid Syndrome and Well-Differentiated Neuroendocrine Tumor

(177-24) A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants with Advanced-Stage Tumors

(179-24) A Phase 1 Dose-Escalation Study of SLV-154 in Subjects with Metastatic Solid Tumors

(186-24) A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants with Advanced/Metastatic Solid Tumors

(188-24) Phase 1 study of ACR-2316 in subjects with advanced solid tumors

(232-24) A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

(237-24) Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors

(240-24) Pilot study of characterization of hereditary cancer-associated germline variants with long-read sequencing (LRS)

(246-23) An open-label, multicenter, first-in-human Phase 1a/1b study to evaluate safety and tolerability of QXL138AM in participants with locally advanced unresectable and/or metastatic solid tumors and multiple myeloma

(266-24) A Phase 1b Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels

Certain clinical trials may not be listed on ClinicalTrials.gov.